JBI-802 is under clinical development by Jubilant Therapeutics and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JBI-802’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JBI-802 is under development for the treatment of melanoma, acute myeloid leukemia(AML), myelodysplastic syndrome, colon cancer, triple negative breast cancer (TNBC), small-cell lung cancer, myeloproliferative neoplasm, neuroendocrine tumors, solid tumor and neuro endocrine prostate cancer (NEPC). It is administered through oral route of administration. The therapeutic candidate acts by targeting both LSD1 and HDAC6.
Jubilant Therapeutics overview
Jubilant Therapeutics a subsidiary of Jubilant Life Sciences Ltd is a biopharmaceutical company that discovers, develops and commercializes gene-therapy medicines for the treatment of cancer, and autoimmune diseases. The company’s pipeline product candidates include LSD1/HDAC6 a novel dual epigenetic inhibitor for treating acute myeloid leukemia (AML); PAD4 inhibitors for the treatment rheumatoid arthritis, psoriasis; PRMT5 inhibitor targeting glioblastoma lymphoma; and PDL-1 small molecule for treating of multiple cancer. Jubilant Therapeutics collaborates with Frazier Healthcare Partners and Checkpoint Therapeutics Inc to develop novel therapies for the treatment of cancer. Jubilant Therapeutics is headquartered in Bedminster, New Jersey, the US.
For a complete picture of JBI-802’s drug-specific PTSR and LoA scores, buy the report here.